Article
Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.
Cancer treatment and research communications - 1 Jan 2022
Agraso Sara, Lázaro Martin, Firvida Xose Luis, Santomé Lucía, Fernández Natalia, Azpitarte Cristina, Leon Luis, Garcia Carme, Hudobro Gerardo, Areses Ma Carmen, Campos Begoña, Quiroga Nazaret, García Jorge, Casal Joaquín
Abstract excerpt
BACKGROUND: In clinical studies, first-line afatinib demonstrated efficacy in Del19-EGFR NSCLC. MATERIALS AND METHODS: This prospective, non-interventional study assessed efficacy and safety of first-line afatinib in patients with advanced/metastatic NSCLC with Del19-EGFR from Galicia (Spain), with a preplanned analysis by age (<70 vs ≥70 years). RESULTS: Median age of 46 patients enrolled was 69.5 years (range...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.